Sundaram Multi Pap Q3FY26 Results: Income up 26%, Net Profit Turns Positive
Sundaram Multi Pap reported a Q3 FY26 profit of ₹1.62 crore against a loss last year. Nine-month profit was ₹2.01 crore. Income for Q3 rose to ₹26.93 crore. The company is awaiting in-principle approval for a preferential issue of equity shares.
The positive financial performance and the announcement of a preferential issue are material events for the company, potentially impacting its financial structure and future growth. However, the absolute profit figures are not exceptionally large, suggesting a medium impact.
The company has shown a significant turnaround from a net loss to a net profit for both the quarter and the nine-month period. Income has also seen an increase, indicating positive business performance.
Sundaram Multi Pap Limited announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025.
For the quarter ended December 31, 2025, the company reported a total income from operations of ₹26.93 crore (2,692.85 lacs), an increase from ₹21.36 crore (2,135.88 lacs) in the corresponding quarter of the previous year. The net profit after tax for the quarter stood at ₹1.62 crore (161.99 lacs), a significant turnaround from a net loss of ₹2.69 crore (268.53 lacs) in the same period last year.
For the nine months ended December 31, 2025, the total income from operations was ₹93.69 crore (9,368.81 lacs), up from ₹87.80 crore (8,779.62 lacs) in the nine months ended December 31, 2024. The net profit after tax for the nine-month period was ₹2.01 crore (200.62 lacs), compared to a net loss of ₹4.27 crore (426.81 lacs) in the prior year period.
The Board of Directors approved these results on February 14, 2026. The company also noted that its EGM on November 12, 2025, approved a proposal for a preferential issue of equity shares, for which in-principle approval from BSE and NSE is awaited.
What to do with a filing like this
Sundaram Multi Pap Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sundaram Multi Pap Limited. Read the original for the full detail.